Table 2.
Univariate Analysis of Overall Survival
| Covariate | Level | N | OS (Months)
|
||
|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | HR P-value | Log-rank P-value | |||
| Postoperative Radiation | Yes | 918 | 0.91 (0.82–1.01) | 0.073 | 0.071 |
| No | 1197 | - | - | ||
|
| |||||
| RT Regional Dose | >60 Gy | 67 | 1.04 (0.78–1.39) | 0.793 | 0.226 |
| 50–60 Gy | 436 | 0.88 (0.77–1.01) | 0.066 | ||
| <50 Gy | 415 | 0.92 (0.80–1.05) | 0.207 | ||
| No post-op radiation | 1197 | - | - | ||
|
| |||||
| Facility Type | Academic/Research Program (Includes NCI) | 847 | 0.84 (0.69–1.02) | 0.083 | 0.219 |
| Comprehensive Community Cancer Program | 1098 | 0.86 (0.71–1.04) | 0.122 | ||
| Community Cancer Program/Other | 170 | - | - | ||
|
| |||||
| Sex | Male | 991 | 1.29 (1.16–1.43) | <.001 | <.001† |
| Female | 1124 | - | - | ||
|
| |||||
| Patient Age | 2115 | 1.01 (1.01–1.02) | <.001 | - | |
|
| |||||
| Race | Other | 262 | 0.93 (0.79–1.09) | 0.376 | 0.375 |
| White | 1831 | - | - | ||
|
| |||||
| Insurance | Not Insured | 41 | 1.14 (0.81–1.62) | 0.450 | <.001† |
| Private Insurance | 963 | 0.79 (0.71–0.88) | <.001 | ||
| Govt. Insurance | 1078 | - | - | ||
|
| |||||
| Income | < $30,000 | 252 | 1.25 (1.06–1.48) | 0.010 | 0.017† |
| $30,000 – $34,999 | 387 | 1.19 (1.02–1.37) | 0.023 | ||
| $35,000 – $45,999 | 539 | 1.16 (1.01–1.32) | 0.031 | ||
| $46,000 + | 836 | - | - | ||
|
| |||||
| Urban/Rural | Urban/Rural | 342 | 1.01 (0.88–1.17) | 0.875 | 0.876 |
| Metro Area | 1655 | - | - | ||
|
| |||||
| Charlson-Deyo Score | 2+ | 185 | 1.22 (1.02–1.47) | 0.034 | 0.014† |
| 1 | 638 | 1.15 (1.03–1.29) | 0.016 | ||
| 0 | 1292 | - | - | ||
|
| |||||
| Year of Diagnosis | 2004 | 673 | 0.94 (0.83–1.07) | 0.356 | 0.332 |
| 2005 | 694 | 1.04 (0.91–1.18) | 0.584 | ||
| 2006 | 748 | - | - | ||
|
| |||||
| Histology | Squamous cell carcinomas | 502 | 1.11 (0.98–1.25) | 0.111 | 0.002† |
| Large cell carcinomas | 131 | 1.22 (0.98–1.51) | 0.074 | ||
| Adenosquamous carcinomas | 75 | 1.56 (1.20–2.04) | <.001 | ||
| Adenocarcinomas | 1407 | - | - | ||
|
| |||||
| Grade | Unknown | 114 | 1.07 (0.77–1.50) | 0.689 | 0.038† |
| 4 | 81 | 1.64 (1.16–2.33) | 0.005 | ||
| 3 | 936 | 1.20 (0.93–1.55) | 0.155 | ||
| 2 | 877 | 1.14 (0.88–1.48) | 0.309 | ||
| 1 | 107 | - | - | ||
|
| |||||
| AJCC Pathologic T | 4 | 134 | 1.64 (1.32–2.03) | <.001 | <.001† |
| 3 | 114 | 1.49 (1.17–1.88) | <.001 | ||
| 2 | 1147 | 1.25 (1.11–1.40) | <.001 | ||
| 0/1 | 712 | - | - | ||
|
| |||||
| Regional Nodes Positive | >=3 | 1007 | 1.30 (1.17–1.45) | <.001 | <.001† |
| 1–2 | 987 | - | - | ||
|
| |||||
| Regional Nodes Examined | >9 | 972 | 0.79 (0.67–0.94) | 0.009 | 0.073 |
| 7–9 | 351 | 0.82 (0.67–1.01) | 0.056 | ||
| 4–6 | 344 | 0.82 (0.67–1.00) | 0.047 | ||
| 1–3 | 221 | - | - | ||
Abbreviations: OS: Overall Survival; HR: Hazard Ratio; RT: Radiotherapy; NCI: National Cancer Institute; AJCC: American Joint Committee on Cancer
†
Significant